# Zurig (Febuxostat) 40mg Efficacy and Safety Trial

> **NCT02600780** · PHASE4 · COMPLETED · sponsor: **Getz Pharma** · enrollment: 50 (actual)

## Conditions studied

- Hyperuricemia

## Interventions

- **DRUG:** Febuxostat
- **DRUG:** Allopurinol

## Key facts

- **NCT ID:** NCT02600780
- **Lead sponsor:** Getz Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-11
- **Primary completion:** 2014-12
- **Final completion:** 2015-03
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2019-08-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02600780

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02600780, "Zurig (Febuxostat) 40mg Efficacy and Safety Trial". Retrieved via AI Analytics 2026-06-06 from https://api.ai-analytics.org/clinical/NCT02600780. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*